Aledade and Aetna are partnering to bring population health to patients and greater accountability of total cost of care to providers, said Travis Broome, vice president of policy at Aledade.
Aledade and Aetna are partnering to bring population health to patients and greater accountability of total cost of care to providers, said Travis Broome, vice president of policy at Aledade.
Transcript
Aledade is partnering with Aetna to expand value-based care in 3 states. How will the partnership improve care and lower costs for patients? What is the partnership focusing on?
So, one of our big beliefs is that we want the total patient panel, right? You know, if we’re going to move away from the 15-minute blocks, it’s best if you can do that for everyone, so it’s always been a mission of Aledade to get as many of our practices' patients under value-based care models, as possible.
So, we work with tons of commercial payers now to that end. The Aetna partnership is one we’re excited about, because you mentioned it’s in 3 states now. Aetna and Aledade both have a national footprint, but at the end of the day it’s all about bringing population health to as many patients as we can, and you know, really when you think about total cost of care accountability, and what it means to be an ACO [accountable care organization], we think of it as excellence in primary care and excellence in population health.
Both of those things are enabled by great partnerships with payers from data—we just heard the CMS administrator talk about data underpins all this—certainly would agree with that from finical right. At the end of the day, these are all small businesses that stay in operation to, you know, partnerships in coordinating benefits for members. So, that is really our, they’re excited about all of our commercial partners for that reason because we want every patient of the practice to get excellence in primary care and excellence in population health and partnerships like the Aetna one make that possible.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More